R
Robert T. Nolte
Researcher at Research Triangle Park
Publications - 30
Citations - 5989
Robert T. Nolte is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Peptide binding & Binding site. The author has an hindex of 25, co-authored 29 publications receiving 5700 citations. Previous affiliations of Robert T. Nolte include Howard Hughes Medical Institute & Harvard University.
Papers
More filters
Journal ArticleDOI
Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma.
Robert T. Nolte,G. B. Wisely,Stefan Westin,Cobb Jeffrey Edmond,Millard H. Lambert,Riki Kurokawa,Michael G. Rosenfeld,Timothy M. Willson,Christopher K. Glass,Michael V. Milburn +9 more
TL;DR: A general mechanism for the assembly of nuclear receptors with co-activators is suggested, based on the observation that two consecutive LXXLL motifs of SRC-1 make identical contacts with both subunits of a PPAR-γ homodimer.
Journal ArticleDOI
Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation.
Eileen M. McInerney,David W. Rose,Sarah E. Flynn,Stefan Westin,Tina-Marie Mullen,Anna Krones,Juan Inostroza,Joseph Torchia,Robert T. Nolte,Nuria Assa-Munt,Michael V. Milburn,Christopher K. Glass,Michael G. Rosenfeld +12 more
TL;DR: Data suggest that the LXXLL-containing motifs have evolved to serve overlapping roles that are likely to permit both receptor-specific and ligand-specific assembly of a coactivator complex, and that these recognition motifs underlie the recruitment of coActivator complexes required for nuclear receptor function.
Journal ArticleDOI
Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators.
Stefan Westin,Riki Kurokawa,Robert T. Nolte,Wisely Gb,Eileen M. McInerney,D W Rose,Michael V. Milburn,Michael G. Rosenfeld,Christopher K. Glass +8 more
TL;DR: Allosteric inhibition of RXR results from a rotation of the RXR AF-2 helix that places it in contact with the RAR coactivator-binding site, allowing RXR ligands to bind and promote the binding of a second LXXLL motif from the same SRC-1 molecule.
Journal ArticleDOI
Atomic Structure of PDE4: Insights into Phosphodiesterase Mechanism and Specificity
Robert X. Xu,Anne M. Hassell,Dana E. Vanderwall,Millard H. Lambert,William D. Holmes,Michael A. Luther,Warren J. Rocque,Michael V. Milburn,Yingdong Zhao,Hengming Ke,Robert T. Nolte +10 more
TL;DR: The three-dimensional structure of the catalytic domain of phosphodiesterase 4B2B to 1.77 angstrom resolution suggests the mechanism of action and basis for specificity and will provide a framework for structure-assisted drug design for members of the phosphodiedterase family.
Journal ArticleDOI
Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor†
Philip A. Harris,Amogh Boloor,Mui Cheung,Rakesh Kumar,Renae M. Crosby,Ronda G. Davis-Ward,Andrea H. Epperly,Kevin Hinkle,Robert N. Hunter,Jennifer H. Johnson,Victoria B. Knick,Christopher P. Laudeman,Deirdre K. Luttrell,Robert A. Mook,Robert T. Nolte,Sharon K. Rudolph,Szewczyk Jerzy Ryszard,Anne T. Truesdale,James Marvin Veal,Liping Wang,Jeffrey A. Stafford +20 more
TL;DR: The key steps starting from an initial screening hit leading to the discovery of pazopanib are described, a potent pan-VEGF receptor (VEGFR) inhibitor under clinical development for renal-cell cancer and other solid tumors.